[Chylous ascites and chylothorax, rare complications of Hodgkin's disease: do they represent a complication of the future?].
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D002916:Chylothorax / Q000209:etiology*; D002915:Chylous Ascites / Q000209:etiology*; D006689:Hodgkin Disease / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008220:Lymphography; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D010166:Palliative Care; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D006834:Hydrazines; D009588:Nitrogen Mustard Compounds; D014750:Vincristine; D011241:Prednisone
Ascite chyleuse et chylothorax, complications rares de la maladie de Hodgkin, représentent-ils une complication d'avenir.